NCT00310180 2026-03-18
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02927912 2026-02-17
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT02912312 2026-01-07
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT02917421 2025-05-04
ART
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting